108 citations
,
February 2008 in “The Journal of urology/The journal of urology” This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.
February 2026 in “NeuroSci” This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.